Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VTAK vs CLPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VTAK Captures Overall Composite Edge (58.1 HOLD vs 40.0 SELL), While CLPT Leads 4–1 on Growth & Valuation Pillars
VTAK Overall Winner
6-Pillar Tally: VTAK 1 – 4 CLPT (1 Tie)
Matrix Metrics: VTAK 5 – 5 CLPT
As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (58.1/100 HOLD vs. 40.0/100 SELL) after splitting the core matrix 5–5 (led by Options & Positioning), while CLPT wins 4–1 across the 6-pillar growth and valuation breakdown. VTAK trades at $0.15 (N/M Forward P/E, -388.1% operating margin) versus CLPT at $8.30 (12.1x Forward P/E, -66.6% operating margin).
- Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. CLPT 40.0/100 SELL) and 0.19β · 76% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VTAK vs CLPT
VTAK
Head-to-Head Winner
Catheter Precision, Inc.
$0.15
-0.66% 1D
Market Cap
$548,639
TTM Revenue
$1.9M
Forward P/E
N/M
Beta / 30D Vol
0.19β · 76% Vol
Unified Composite Score
58.1
HOLD
Tech 72.0
Fund 70.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
CLPT
ClearPoint Neuro, Inc. Common Stock
$8.30
-2.12% 1D
Market Cap
$271.8M
TTM Revenue
$45M
Forward P/E
12.1x
Beta / 30D Vol
1.90β · 85% Vol
Unified Composite Score
40.0
SELL
Tech 30.0
Fund 50.0
Flow 64.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (VTAK 1 – 4 CLPT)
1. Valuation Multiples
CLPT
Forward P/E
N/M
12.1x
Trailing P/E
N/M
12.1x
PEG Ratio
N/M
0.60x
EV / Revenue
0.3x
6.6x
2. Growth & Scale
CLPT
Revenue Growth (YoY)
+380.7%
+36.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1.9M
$45M
Market Cap
$548,639
$271.8M
3. Profitability & Quality
CLPT
Gross Margin
47.7%
61.4%
Operating Margin
-388.1%
-66.6%
Net Profit Margin
0.0%
-79.4%
Return on Equity (ROE)
-111.3%
-167.5%
4. Balance Sheet & Cash Flow
CLPT
Cash Generation (TTM)
-$10M EBITDA
-$33M
Cash Flow Margin
N/A
-73.0%
Net Cash / Leverage
$4.87 Book/Sh · -111.3% ROE
$28M Net Debt (2.70x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
VTAK
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
68.7% (2nd %ile)
Put/Call OI Skew
N/A
1.17x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VTAK (5) vs CLPT (5)| Institutional Metric | VTAK | CLPT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $548,639 | $271.8M | CLPT | |
| Trailing P/E Ratio | N/M | 12.1x | CLPT | |
| Forward P/E Ratio | N/M | 12.1x | CLPT | |
| Revenue Growth (YoY) | +380.7% | +36.3% | VTAK | |
| Operating Margin (TTM) | -388.1% | -66.6% | CLPT | |
| Net Profit Margin | 0.0% | -79.4% | VTAK | |
| Return on Equity (ROE) | -111.3% | -167.5% | VTAK | |
| 52-Week Range Position | 1% ($0–$3) | 2% ($8–$20) | CLPT | |
| Beta / 30D Volatility | 0.19β · 76% Vol | 1.90β · 85% Vol | VTAK | |
| Unified Institutional Score | 58.1 / 100 (HOLD) | 40.0 / 100 (SELL) | VTAK | |
| Trailing 12M Revenue (USD) | $1.9M | $45M | Scale | |
| Gross Profit Margin (TTM) | 47.7% | 61.4% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.3x EV/Rev | 0.60x PEG · 6.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) | -$33M ($28M Net Debt (2.70x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CLPT +0.9 pp
3M Horizon
CLPT +40.82 pp
6M Horizon
CLPT +100.04 pp
1Y Horizon
CLPT +62.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VTAK Revenue | CLPT Revenue | VTAK Op. Margin | CLPT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $10M | $10M | -498.0% | -71.4% | CLPT |
| FY2019 | $10M | $10M | -801.9% | -41.0% | CLPT |
| FY2020 | $0M | $10M | -13668.3% | -48.5% | CLPT |
| FY2021 | $0M | $20M | -133027.3% | -82.1% | CLPT |
| FY2022 | $0M | $20M | -192578.6% | -79.5% | CLPT |
| FY2023 | $0M | $20M | -17674.0% | -93.7% | CLPT |
| FY2024 | $0M | $30M | -2676.9% | -62.9% | CLPT |
| FY2025 | $0M | $40M | -2581.6% | -65.4% | CLPT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VTAK
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CLPT
BREAKDOWN
Current IV
68.7%
IV Percentile
2nd %ile
Put/Call OI Skew
1.17x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact CLPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VTAK Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CLPT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ VTAK vs CLPT Key Questions & Quantitative Answers
As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (58.1/100 HOLD vs. 40.0/100 SELL) after splitting the core matrix 5–5 (led by Options & Positioning), while CLPT wins 4–1 across the 6-pillar growth and valuation breakdown. VTAK trades at $0.15 (N/M Forward P/E, -388.1% operating margin) versus CLPT at $8.30 (12.1x Forward P/E, -66.6% operating margin). Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. CLPT 40.0/100 SELL) and 0.19β · 76% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLPT leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with CLPT at +36.3% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (61.4% gross margin, -66.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTAK cumulative revenue shifted +0.0% while CLPT shifted +300.0%. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLPT.
CLPT screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas CLPT trades at 12.1x Forward P/E, 12.1x Trailing P/E, 0.60x PEG, and 6.6x EV/Revenue (-73.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus CLPT (-167.5% ROE) capital efficiency.
In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, CLPT carries 68.7% implied volatility (2nd %ile, Compressed (<25th %ile)), a 1.17x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.90β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CLPT vs VTAK · Reverse Pair
VTAK vs EPOW
· Sector Peer
CLPT vs TMDX
· Sector Peer
CLPT vs HROW
· Sector Peer
CLPT vs PSNL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma